Wet AMD biotech stock soars over 200% as lead as­set match­es Re­gen­eron’s Eylea in PhII test

Eye­Point Phar­ma­ceu­ti­cals’ wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD) ther­a­py has demon­strat­ed non-in­fe­ri­or­i­ty to Re­gen­eron’s Eylea, even with a less fre­quent dos­ing reg­i­men in a mid-stage study …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER